Dosages for treatment with anti-egfr antibodies
Patent Information
- Authority / Receiving Office
- CN · China
- Current Assignee / Owner
- GENENTECH INC
- Publication Date
- 2008-12-31
- Estimated Expiration
- Not applicable · inactive patent
Smart Images
Figure 1 
Figure 2 
Figure 3
Abstract
Description
[0001] This case is a divisional application of an invention application with a filing date of August 25, 2000, a Chinese application number of 00814590.3, and an invention title of "Preparation for Anti-ErbB2 Antibody Therapy". field of invention
[0002] The present invention relates to the treatment of disorders characterized by overexpression of ErbB2 or by expression of epidermal growth factor receptor (EGFR), comprising administering to a human or animal suffering from said disorder a therapeutic amount of an antibody that will bind ErbB2. More specifically, the invention relates to the treatment of human patients predisposed to or diagnosed with ErbB2-overexpressing or EGFR-expressing cancers by administering a frontal load during treatment by intravenous and / or subcutaneous administration amount of anti-ErbB2 antibody. The present invention optionally includes the use of anti-ErbB2 antibodies in combination with chemotherapeutic agents, such as but not limited to taxoi...